English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Voriconazole (VOZ) is an antifungal drug having poor aqueous solubility. VOZ nanostructured lipid carrier (VNLC) was prepared by using melt emulsification followed by ultrasonication technique. The VNLCs were optimized by 3 2  full factorial design using Design-Expert® software. The optimized VNLC had a particle size, zeta potential and entrapment efficiency of 205.8 nm, −27.1 mV and 78.85%, respectively. The optimized VNLC was further loaded in thermosensitive  in situ  gel.  In vitro  release studies of VNLC gel showed sustained release of the drug (98.84 ± 1.26%) for up to 24 h. The  ex vivo  permeation studies showed higher penetration for the VNLC gel as compared to plain VOZ gel. The  in vitro  antifungal assay showed higher efficacy of VNLC than that of plain VOZ. The HET-CAM test of the VNLC gel showed no irritation and thus was found to be suitable for vaginal administration. Thus, it can be concluded that the developed VNLC gel showed a sustained release pattern with higher drug localization in the vaginal tissue and thus can offer improved treatment of vaginal candidiasis.

Sustained vaginal delivery of in situ gel containing Voriconazole nanostructured lipid carrier: formulation, in vitro and ex vivo evaluation